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ABSTRACT
The social aspect of overactive bladder syndrome (OAB) and the lack of objective diagnostic methods for this syndrome 
have spurred research into its potential biomarkers which can constitute useful diagnostic tools, while also allowing the 
evaluation of the intensity of clinical symptoms and the efficacy of implemented pharmacotherapy in OAB patients. Due 
to the complex etiopathogenesis of this syndrome, the researchers are seeking biomarkers connected with inflammation 
or nerve growth. The aim of this review was to analyse the latest literature data regarding potential biomarkers in OAB. The 
most promising opportunities are connected with the diagnostic use of the nerve growth factor (NGF), the brain derived 
neurotrophic factor (BDNF), C-reactive protein (CRP), prostaglandins and cytokines. Despite the most promising results to 
date having been obtained with regards to neurotrophic factors, it seems that, at the moment, none of these meets the 
criteria for becoming an isolated OAB marker. It is also suggested that the combined use of several biomarkers will facilitate 
obtaining the appropriate level of specificity and selectivity to allow their use in clinical practice.
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INTRODUCTION
OAB is a social disease which affects more than 10% of 
adults. It is a symptom-based condition, defined as a syn-
drome characterised by the presence of urgency, with or 
without urge urinary incontinence, which is usually accom-
panied by frequency and nocturia, in the absence of proven 
pathologies. Urinary urgency is a subjective symptom re-
ported by patients, which is considered essential for making 
an accurate diagnosis. At present, the basis of OAB diagnos-
tics is constituted by medical interview and the analysis of 
bladder diaries. Thus, there is a great demand for developing 
objective testing which would become a useful diagnostic 
tool and allow the assessment of the intensity of observed 
clinical symptoms and the monitoring of treatment efficacy.
Attempts are made to identify a non-invasive, cost-ef-
fective, sensitive and specific biomarker which could be 
detected in biological samples, using a simple and repeti-
tive method. Below is a short review of the potential OAB 
biomarkers and the possibilities of their application in clini-
cal practice.
BDNF
BDNF plays an important role in the normal function-
ing of sensory neurons. It belongs to neurotrophic factors 
(including NGF, BDNF, NT3 NT4) and is secreted from the 
urothelium. It binds with TrkB receptors present in both 
the urothelium and the afferent fibres of the bladder. Fur-
thermore, it has a trophic effect on nerve tissue, and plays 
an important role in nociceptive processes, at both the 
spinal cord and supra-spinal levels, and also in inflammatory 
processes. Its presence was detected in terminal endings 
of sensory fibres, which where the presence of CGRP and 
substance P is found. It is suggested that the expression 
of BDNF is modelled by NGF. Its synthesis is significantly 
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increased in the case of spinal cord injuries and chronic 
cystitis. The results of preclinical trials have shown that the 
acute intrathecal (into the spine) administration of BDNF 
induces an increase in urinary frequency, an effect which 
was not observed in the case of chronic administration [1].
The secretion of BDNF is usually induced by an increase 
in NGF synthesis in an inflamed tissue. Since BDNF plays 
an important role in the etiopathogenesis of both pain 
and inflammation, the work was undertaken with the aim 
to evaluate its role in the etiopathogenesis of cystitis and 
OAB. It was found that chemically induced cystitis changed 
the properties of afferent fibres in the spinal cord and dor-
sal root ganglia. It is suggested that BDNF is responsible 
for these adaptive changes and neuronal plasticity. It has 
been proven that the expression of TrkB receptors was sig-
nificantly increased in L1, L2, L6 and S1 dorsal-root ganglia 
in the case of acute cystitis induced by cyclophosphamide, 
but not in chronic cystitis cases. These studies have con-
firmed that the level of BDNF is much higher in animals with 
cyclophosphamide-induced bladder hyperactivity.
There are studies proving that BDNF sequestration has 
a positive effect on bladder function in cystitis. Importantly, 
BDNF sequestration does not affect the physiological mic-
turition reflex, which proves that BDNF modulates bladder 
activity only in the case of its dysfunction. It has been noted 
that the BDNF/creatinine (pg/mg) ratio is low in healthy 
people and is independent of gender or the circumstances 
of sample collection. A very significant increase in BDNF 
has, in turn, been found in OAB patients, in particular in 
people with OAB wet. Interestingly, the level of BDNF is 
increased in people with depression, usually coexisting 
with OAB, which might suggest this is a common element 
in the etiopathogenesis of these two diseases. Thus, it seems 
that urinary BDNF can become a valuable biomarker in OAB 
diagnostics. It is particularly worth pointing out that the 
conducted comparative analysis of the receiver-operator 
characteristic curves of urinary NGF/creatinine and urinary 
BDNF/creatinine in OAB patients demonstrated that BDNF 
had a better area under the curve than NGF [2].
BDNF was also analysed in the context of its possible 
use in assessing the effectiveness of OAB treatment. As 
botulinum toxin displays analgesic effects, which result from 
the inhibition of nociceptive neurotransmission in the spinal 
cord and the prevention of neurogenic inflammation, it was 
verified whether its administration into the bladder triangle 
in patients with bladder pain syndrome could affect BDNF 
levels. It was found that neurotrophin concentrations signifi-
cantly decreased after one month from the administration 
of neurotoxin, which proved to correlate with a drop in pain 
intensity on a visual analogue scale. The patients also noted 
a subjective improvement in terms of daytime frequency 
and nocturia, one and three months following the admin-
istration of the botulinum toxin. The BDNF level increased 
gradually to reach the baseline value six months after the 
administration of the neurotoxin. Another clinical study 
proved that BDNF/creatinine decreased as a result of treat-
ment with cholinergic blocking agents. What is particularly 
interesting is that the drop in BDNF/creatinine correlated 
with a decrease in urinary urgency, which was not observed 
in the case of NGF/creatinine [3].
In general, the BDNF concentration in urine is rela-
tively low irrespectively of the time of sample collection. 
It has been proved that the BDNF/creatinine level is sig-
nificantly higher in OAB patients than in healthy individu-
als (980.3 ± 1,774.8 vs. 110.4 ± 159.5). Interestingly, after 
three-month treatment its level in the OAB group was signifi-
cantly reduced (980.3 ± 1,774.8 vs. 399.5 ± 487). This decrease 
was accompanied by a reduction in clinical symptoms (Inde-
vus Urgency Severity Scale scores 3.29 ± 0.59 vs. 3.18 ± 0.39). 
Thus, it seems that BDNF can become an acute biomarker of 
OAB treatment efficacy. The results of the conducted studies 
showed that BDNF proved superior to NGF in OAB diagnos-
tics. An obstacle to adapting BDNF as an OAB biomarker 
is the lack of standardised data concerning its reference 
values in healthy people, and the lack of knowledge of the 
threshold value above which this biomarker would show 
sensitivity and specificity in OAB diagnostics [4].
CRP AND CYTOKINES
It seems that cytokines can become a useful biomarker 
in OAB diagnostics, as their level in biofluids shows a ten-
dency to increase in inflammatory processes. The results of 
clinical trials have shown that the level of the soluble fraction 
of the CD40 ligand (sCD40L) and monocyte chemotactic 
protein-1 (MCP-1) was several times higher in the urine of 
OAB patients when compared with healthy controls. A sig-
nificant difference between the groups was also found in 
relation to growth-related oncogene (GRO-α), epidermal 
growth factor (EGF), and macrophage inflammatory protein 
(MIP- 1β), IL-12p70/p40, IL-5, IL-10 and sIL-2Rα. It was also 
proved that the level of cytokines (MCP1, TARC, PARC and 
Fas/TNFRSF6) was increased in OAB patients, to the statisti-
cally significant extent.
Given that CRP is a recognised acute-phase marker of 
inflammation, which is synthesised in the liver as a response 
to the factors secreted by macrophages and adipocytes, the 
studies were also undertaken to examine this protein in the 
context of using it as an OAB biomarker. The tests included 
patients with OAB wet and dry, comparing CRP levels in 
the urine, blood and bladder tissue with their counterparts 
in healthy controls. The CRP levels were higher in patients 
of both studied groups when compared with the control 
group. At the same time, it was noted that the blood serum 
CRP levels, although higher in OAB patients, failed to reach 
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the values usually observed in the case of inflammation. 
Interestingly, it was also found that the CRP level was statisti-
cally significantly higher in OAB wet patients than in the OAB 
dry group. At the same time, it was observed that urinary 
and bladder CRP levels were considerably lower than the 
serum CRP level [6].
Other trials revealed a correlation between serum-CRP 
levels and episodes of urgency in patients with benign 
prostatic hyperplasia. The patients who reported urgency 
symptoms had significantly higher CRP levels than healthy 
individuals. At the same time, intensified OAB symptoms 
were noted in people with CRP levels > 0.3 mg/dL than in 
those with CRP levels < 0.3 mg/dL. High serum CRP levels 
were also found in women with OAB, with statistically higher 
values noted in the OAB wet group when compared with 
female patients with bladder hypersensitivity, but without 
the urodynamic symptoms of detrusor overactivity. Interest-
ingly, a correlation was found between an increase in CRP 
level and a drop in the maximum urinary flow rates. Higher 
values of the maximum urinary flow rate and the body 
mass index turned out to be two independent factors af-
fecting the CRP level. It was also proven that a CRP level of 
1–3 mg/L entailed an increase in the risk of OAB symptoms, 
which might suggest that the inflammatory process plays 
an important role in the etiopathogenesis of OAB [7].
It seems that due to the very low values of CRP present in 
the urine and bladder which are detectable only in specialist 
research centres, it will be difficult to develop a urinary assay 
to become commonly available and ready for use in every-
day clinical practice in the nearest future. It is also of essence 
that CRP is not a characteristic marker of pathophisiological 
processes underlying OAB, but only a non-specific marker 
of inflammation. It seems that at present it has too poor 
sensitivity and selectivity to become an isolated biomarker 
of OAB. However, it can be useful when combined with other 
biomarkers such as NGF or BDNF. Such combinations might 
significantly increase its diagnostic value [8].
PROSTANOIDS
Prostanoids (PGs) have a modulating effect on the func-
tioning of the lower urinary tract. They play an important 
role in maintaining the basal tone of the urinary bladder, 
and impact on the afferent nerves which supply it. PGs are 
synthesised in both the urothelium and the bladder detru-
sor. Their synthesis increases in response to the stimulation 
of bladder nerve endings, detrusor contraction, urothelial 
damage, or inflammation. Their effect on the micturition re-
flex includes the lowering of the threshold value of impulses 
necessary to generate detrusor contraction. Therefore, it 
seems that there might be a correlation between the PGs 
level and the intensification of symptoms reported by OAB 
patients [9].Prostaglandins increase the afferent impulsation 
of the voiding reflex, leading to the occurrence of OAB symp-
toms. It has been found that COX-2 blocking with the use 
of non-selective cyclooxygenase inhibitors (ketoprofenum 
or indometacinum) increases the voiding threshold and the 
functional bladder volume in patients with detrusor hyper-
reflexia. Despite the fact that the subjective symptoms of 
OAB are improved, those medications do not modulate the 
cystometric parameters characteristic of DO in urodynamic 
tests. Such urodynamic changes, in turn, have been found 
after the administration of flurbiprofen, which led to the 
reduction in urgency and an increase in voiding volume. 
Due to the negative impacts of COX-2 inhibitors on the 
cardiovascular system, it seems that an interesting treatment 
option can be not so much the effects on COX but rather the 
determination of receptors for prostanoids. These theories 
find confirmation in the results of trials in which the animals 
genetically devoid of the EP1 receptor have not displayed DO 
symptoms after the instillation of the bladder with a solution 
containing prostaglandins [10].
Preclinical trials have shown that administration of PGs 
to the lumen of the urethra induces its relaxation, while 
intravesical instillation causes detrusor contraction. The 
results of the clinical trials conducted have proved that 
the PGE2 and PGF2α levels in the urine of OAB patients are 
considerably higher than in healthy people. A correlation 
has also been detected between the PGE2 level in the urine 
and the maximum cystometric capacity, and the volume 
to first desire to void. Such a correlation was not observed 
in relation to NGF, PGF2α and PGI2. In turn, the intravesical 
administration of PGE2 proved to lead to an increase in 
maximal volume pressure and a drop in the voided volume. 
There are also studies in which the authors did not find any 
significant differences in PGE2 levels between OAB patients 
and the controls [11].
The role of PGs in OAB diagnostics remains controversial. 
According to some researchers, PGE2 levels are superior to 
NGF in diagnosing OAB. Interestingly, it was proved that 
the PGE2 and PGF2α levels in patients with detrusor under-
activity, which had been confirmed in urodynamic tests, 
were considerably lower when compared with the group 
displaying the signs of DO. The differences between the 
groups in terms of PGI2 were not observed [12].
ATP (ADENOSINE TRIPHOSPHATE)
ATP is secreted by urothelium in response to bladder 
contraction. It has been demonstrated that stretch-acti-
vated ATP release is markedly increased in OAB patients 
and whenever a decrease in the extracellular pH level is 
induced by bladder hypoxia. ATP mediates detrusor contrac-
tions induced by adrenergic and cholinergic neurotrans-
missions  [13]. An in vitro study has shown increased ATP 
secretion by urothelium cells and cholinergic nerve endings 
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in OAB patients. The ATP level is now being investigated as 
a potential OAB biomarker. Preliminary results revealed that 
urinary ATP was increased in OAB (wet and dry) patients, 
which correlates with a reduced first desire to void in urody-
namic tests [14]. Importantly, its level decreased in patients 
positively responding to pharmacological treatment with 
antimuscarinics. It was also shown that the urinary ATP to 
urine creatinine levels (ATP/Cr) ratio was significantly higher 
in patients with OAB and DO features, compared with the 
control group. An increased ATP/Cr correlated with a de-
creased mean voided volume. The area under the curve was 
proportional to the increased ATP/Cr level, which suggests 
that it can be a very sensitive biomarker of OD in patients 
with OAB symptoms [15].
NGF
The NGF action mechanism is mediated by two types of 
receptor: TrkA — with high affinity to NGF, whose density 
increases in inflammatory processes, and p75 — with low 
affinity, whose high expression was found in the urothelium 
of the patients with OAB symptoms. Apart from its impact 
on the above-mentioned types of receptors, NGF also affects 
the functioning of potential-dependent sodium channels 
(Nav 1.8, SNS, PN3) as well as NK and TRPV1 receptors [16].
The results of preclinical trials have confirmed that the 
intravesical instillation of NGF causes OAB, increasing af-
ferent impulsation through a rise in TRPV1 receptor expres-
sion. DO symptoms could be reversed by NGF-neutralising 
antibodies. Thus, the blocking of receptors to NGF seems 
to be an interesting option for OAB pharmacotherapy [17].
A number of studies confirmed a positive correlation 
between increased NGF and OAB or DO symptoms. Pre-clin-
ical study results demonstrated that this neurotrophin is 
profusely secreted by urothelial cells and smooth muscle 
cells in the detrusor of animals with a hyperactive bladder. 
It was proved that the intravesical instillation of NGF led to 
reduced intercontraction intervals and bladder capacity, 
which was indirectly confirmed by observations involving 
a TrkA receptor antagonist, which reduced the increased 
contractile activity of the detrusor in animals with spinal 
cord injury and interstitial cystitis (IC) [18, 19]. Interestingly, 
TRPV1 knockout animals, when administered NGF, did not 
develop DO symptoms, which might suggest that TRPV1 is 
a downstream receptor for NGF [20].
Based on the results of the pre-clinical studies, it was 
hypothesised that increased NGF levels in urine could sen-
sitise afferent fibres in the bladder and, as a result, lead to 
the development of DO. This claim was supported by the 
clinical study which proved urine NGF levels to be much 
higher in OAB, DO, BOO and IC patients, compared with 
healthy populations. In relation to OAB, these differences 
were particularly significant (11-fold). Interestingly, statisti-
cally significant differences in NGF levels were also found 
between OAB wet and OAB dry patients, and a positive 
correlation was established between urgency and urinary 
NGF levels. Patients with Indevus Urgency Severity Scale 
scores ≥ 3 had considerably higher average NGF levels 
than those with scores ≤ 2. The results of studies on NGF 
sensitivity and specificity are of special importance in terms 
of the application in clinical practice. Specifically, it was 
demonstrated that when OAB patients were diagnosed 
using the NGF/creatinine ratio, the specificity was 93.8 %, 
and the sensitivity 67.9% [21]. It is suggested that the cut-off 
value for this parameter should be > 200 pg/mg. 
The impact of pharmacotherapy on NGF levels in pa-
tients with OAB was also analysed. Therapy employing 
cholinergic blocking agents produced a decrease in this 
neurotrophin corresponding to the reduction in USS scores, 
which returned to their initial values after pharmacotherapy 
was discontinued. Consistent results were produced when 
patients with neurogenic bladders were administered botu-
linum toxin. These observations could suggest that NGF 
might become more than just a useful marker for OAB di-
agnosis, but also prove applicable for assessing the efficacy 
of pharmacological treatment [22].
ULTRASOUND
In patients with bladder outlet obstruction (BOO), OAB 
diagnostics has used the ultrasound measurement of blad-
der wall thickness (BWT) or only detrusor thickness (DT). 
For both these parameters, the measurements proved to 
be significantly higher among OAB patients than in healthy 
controls. This might have been due to bladder hypertro-
phy induced by its excessive contractibility. Some studies 
showed that increased DT correlated with greater urgency 
reported by patients. BWT measurements were also taken 
using intravaginal ultrasound in patients with idiopathic 
DO. It was found that in 58.7% of the analysed patients the 
average BWT was above 5 mm, of whom as many as 94% 
exhibited urodynamic DO characteristics [23, 24]. Only in 
1.6 % of the patients with DO symptoms, BWT was ≤ 3 mm. 
Based on the above-mentioned findings, it is proposed that 
a BWT of 5 mm should be considered the limit for ultrasound 
screening tests for OAB. A positive correlation has also been 
found between the presence of OAB symptoms and high 
BWT and DT. Furthermore, BWT measurement makes it pos-
sible to distinguish between patients with BOO and those 
with clinical symptoms of stress urinary incontinence, which 
has significant clinical implications, since it can be used as 
the basis for targeted therapy in specific patients. Interest-
ingly, DWT levels were reduced following successful treat-
ment with cholinergic blocking agents [25, 26].
A problem which hinders the widespread use of BWT 
and DT is the lack of standardised measurement proce-
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dures for these parameters. It has not been unequivocally 
determined whether these should be measured on a full 
or empty bladder. If on a full bladder, then what should be 
the volume? The majority of facilities prefer an transvagi-
nal procedure, but some practitioners advocate that these 
measurements be performed transperineally [27, 28].
Some studies have demonstrated that DT levels in OAB 
patients show considerable diversification, thus making the 
results statistically insignificant, despite the clear tendency 
towards increased BWT and DT in OAW wet populations. This 
might be due to the use of various USG scanners across 
different studies, and, consequently, the resolution of the 
produced images. It is believed that, in the future, DT can be-
come a pathognomonic marker for DO. This claim is based 
on the assumption that involuntary isometric bladder con-
tractions induce bladder hypertrophy, which translates into 
the ultrasound-measured thickness of its detrusor muscle. 
BWT and DT measurements are considered a more reliable 
DO marker than cystometric measurements, especially in 
relation to patients with BOO [29, 30].
SUMMARY
The clinical trials conducted have identified several 
potential OAB biomarkers, including nerve growth factor, 
brain derived neurotrophic factor, C-reactive protein, pros-
taglandins and cytokines. In terms of sensitivity, specific-
ity, cost- and time-effectiveness, it seems that, when used 
together, these markers can have greater diagnostic value 
and applicability in everyday clinical practice.
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